Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mogens Vyberg

Showing results (91-100 of 102) with videos related to

Pageof 11
Sort By:
Applied Immunohistochemistry & Molecular Morphology : AIMM|February 10, 2017
Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine - Part 2: Immunohistochemistry Test Performance CharacteristicsEmina E Torlakovic, Carol C Cheung, Corrado D'Arrigo, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|December 13, 2016
Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine: Part 4: Tissue Tools for Quality Assurance in ImmunohistochemistryCarol C Cheung, Corrado D'Arrigo, Manfred Dietel, et al.
Journal of Translational Medicine|October 21, 2016
Excerpts from the 1st international NTNU symposium on current and future clinical biomarkers of cancer: innovation and implementation, June 16th and 17th 2016, Trondheim, NorwayAna I Robles, Karina Standahl Olsen, Dana W T Tsui, et al.
American Journal of Physiology. Gastrointestinal and Liver Physiology|August 6, 2024
Hepatic steatosis and not type 2 diabetes, body mass index, or hepatic fibrosis associates with hyperglucagonemia in individuals with steatotic liver diseaseSasha A S Kjeldsen, Mikkel P Werge, Josephine Grandt, et al.
American Journal of Physiology. Gastrointestinal and Liver Physiology|April 16, 2024
Patients with autoimmune liver disease have glucose disturbances that mechanistically differ from steatotic liver diseaseAnne-Sofie H Jensen, Henriette Ytting, Mikkel P Werge, et al.
Alimentary Pharmacology & Therapeutics|July 17, 2025
Diagnostics of Autoimmune Hepatitis Enabled by Non-Invasive Clinical ProteomicsAnne-Sofie Houlberg Jensen, Henriette Ytting, Annelaura Bach Nielsen, et al.
Elife|October 3, 2024
Evaluation of Gremlin-1 as a therapeutic target in metabolic dysfunction-associated steatohepatitisPaul Horn, Jenny Norlin, Kasper Almholt, et al.
Hepatology (Baltimore, Md.)|June 24, 2026
Decoding fibrosis: Transcriptomic and clinical insights via AI-derived collagen deposition phenotypes in MASLDMarta Wojciechowska, Mira Thing, Yang Hu, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|May 3, 2025
Circulating and hepatic levels of growth differentiation factor 15 in patients with metabolic dysfunction-associated steatotic liver diseaseMikkel Parsberg Werge, Josephine Grandt, Mira Thing, et al.
Annals of Hepatology|September 1, 2025
Alterations in one-carbon metabolism in metabolic dysfunction associated steatotic liver disease may be modified by semaglutideMikkel Parsberg Werge, Adrian McCann, Elias Badal Rashu, et al.
Pageof 11

Showing results (91-100 of 102) with videos related to

Sort By:
Pageof 11
Applied Immunohistochemistry & Molecular Morphology : AIMM|February 10, 2017
Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine - Part 2: Immunohistochemistry Test Performance CharacteristicsEmina E Torlakovic, Carol C Cheung, Corrado D'Arrigo, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|December 13, 2016
Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine: Part 4: Tissue Tools for Quality Assurance in ImmunohistochemistryCarol C Cheung, Corrado D'Arrigo, Manfred Dietel, et al.
Journal of Translational Medicine|October 21, 2016
Excerpts from the 1st international NTNU symposium on current and future clinical biomarkers of cancer: innovation and implementation, June 16th and 17th 2016, Trondheim, NorwayAna I Robles, Karina Standahl Olsen, Dana W T Tsui, et al.
American Journal of Physiology. Gastrointestinal and Liver Physiology|August 6, 2024
Hepatic steatosis and not type 2 diabetes, body mass index, or hepatic fibrosis associates with hyperglucagonemia in individuals with steatotic liver diseaseSasha A S Kjeldsen, Mikkel P Werge, Josephine Grandt, et al.
American Journal of Physiology. Gastrointestinal and Liver Physiology|April 16, 2024
Patients with autoimmune liver disease have glucose disturbances that mechanistically differ from steatotic liver diseaseAnne-Sofie H Jensen, Henriette Ytting, Mikkel P Werge, et al.
Alimentary Pharmacology & Therapeutics|July 17, 2025
Diagnostics of Autoimmune Hepatitis Enabled by Non-Invasive Clinical ProteomicsAnne-Sofie Houlberg Jensen, Henriette Ytting, Annelaura Bach Nielsen, et al.
Elife|October 3, 2024
Evaluation of Gremlin-1 as a therapeutic target in metabolic dysfunction-associated steatohepatitisPaul Horn, Jenny Norlin, Kasper Almholt, et al.
Hepatology (Baltimore, Md.)|June 24, 2026
Decoding fibrosis: Transcriptomic and clinical insights via AI-derived collagen deposition phenotypes in MASLDMarta Wojciechowska, Mira Thing, Yang Hu, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|May 3, 2025
Circulating and hepatic levels of growth differentiation factor 15 in patients with metabolic dysfunction-associated steatotic liver diseaseMikkel Parsberg Werge, Josephine Grandt, Mira Thing, et al.
Annals of Hepatology|September 1, 2025
Alterations in one-carbon metabolism in metabolic dysfunction associated steatotic liver disease may be modified by semaglutideMikkel Parsberg Werge, Adrian McCann, Elias Badal Rashu, et al.
Pageof 11